GSK ESMO
Biotech

ESMO: GSK cancer R&D chief says data ‘reinforces belief’ in mo-rez

GSK’s cancer R&D chief suggested the latest slice of data “reinforce[d] our belief in the asset,” as the ADC races through a clutch of phase 3 trials.
James Waldron Oct 23, 2026 6:05pm
Gilead

Gilead to buy PepStar’s oral IL-23 drug for $1.3B upfront

Oct 23, 2026 3:25am
Eli Lilly Lilly

ESMO: Lilly ADC sees 79% ORR in competitive ovarian cancer space

Oct 24, 2026 2:30am
Takeda booth at AACR 2026

ESMO: Takeda’s $1B bet ‘absolutely’ pays off with ADC ph. 3 win

Oct 23, 2026 8:48am
cancer cell split mitosis breast cancer metastasize

ESMO: Why Zentalis is already dreaming of launching WEE1 drug

Oct 23, 2026 10:15am
Boehringer Ingelheim booth at AACR 2026

ESMO: Boehringer builds case for late-phase rival to Imdelltra

Oct 23, 2026 10:30am
More News

Gilead to buy PepStar’s oral IL-23 drug for $1.3B upfront

Oct 23, 2026 11:20am

Bolt strikes Prana reverse merger alongside $120M financing

Oct 23, 2026 10:21am

GSK's Waterhouse tapped to helm struggling CSL—Chutes & Ladders

Oct 23, 2026 8:30am

BMS leads Pathos' $237M series E alongside Alzheimer's link-up

Oct 23, 2026 8:00am